Tesamorelin + Ipamorelin Research Guide

Full name: Tesamorelin/Ipamorelin Combination

A synergistic combination of tesamorelin (GHRH analog) and ipamorelin (selective GHRP) that produces robust, pulsatile growth hormone release. The GHRH+GHRP pairing creates a multiplicative GH response greater than either compound alone.

How Tesamorelin + Ipamorelin Works

Tesamorelin stimulates GH release by activating GHRH receptors on pituitary somatotrophs. Ipamorelin amplifies the pulse by acting on ghrelin/GHS receptors. Together they produce a synergistic "1+1=3" GH release while maintaining physiological pulsatility.

Dosing Protocol

• Typical dose: Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg
• Frequency: Once daily (before bed) or twice daily
• Duration: 3-6 months
• Route: Subcutaneous injection

Reported Benefits

• Significant fat loss (especially visceral/abdominal)
• Lean muscle gains
• Improved sleep quality
• Enhanced recovery
• Anti-aging effects
• Better body composition without exogenous HGH side effects

Potential Side Effects

• Injection site reactions
• Mild water retention
• Numbness/tingling (transient)
• Increased hunger (mild)
• Headache (uncommon)

Research Citations

1. GHRH + GHRP synergy on GH release (2014) - Combined GHRH + GHRP administration produced 3-5x greater GH release than either peptide alone in healthy adults.
2. Tesamorelin/Ipamorelin body composition (2022) - Combination therapy for 12 weeks reduced visceral fat by 15-20% and increased lean mass in GH-deficient adults.

Related Growth Hormone Compounds

• CJC-1295 - Full Profile
• Ipamorelin - Full Profile
• MK-677 (Ibutamoren) - Full Profile
• Sermorelin - Full Profile
• Tesamorelin - Full Profile
• GHRP-2 - Full Profile

View full Tesamorelin + Ipamorelin profile with 3D molecule viewer →